WO2008076883A2 - Triazine derivatives and their therapeutical applications - Google Patents
Triazine derivatives and their therapeutical applications Download PDFInfo
- Publication number
- WO2008076883A2 WO2008076883A2 PCT/US2007/087576 US2007087576W WO2008076883A2 WO 2008076883 A2 WO2008076883 A2 WO 2008076883A2 US 2007087576 W US2007087576 W US 2007087576W WO 2008076883 A2 WO2008076883 A2 WO 2008076883A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloride
- alkyl
- compound
- disease
- sulfate
- Prior art date
Links
- 0 CN1CC*CC1 Chemical compound CN1CC*CC1 0.000 description 2
- UTGXEZIHYRVCAJ-JECWYVHBSA-N CCC(C[C@@H](C)NC(Cl)=N)C(C)Cl Chemical compound CCC(C[C@@H](C)NC(Cl)=N)C(C)Cl UTGXEZIHYRVCAJ-JECWYVHBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of triazine compounds to modulate protein kinases and for treating protein kinase-mediated diseases.
- Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell. Protein kinases, containing a similar 250-300 amino acid catalytic domain, catalyze the phosphorylation of target protein substrates,
- the kinases may be categorized into families by the substrates in the phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, lipids, etc.). Tyrosine phosphorylation is a central event in the regulation of a variety of biological processes such as cell proliferation, migration, differentiation and survival, Several families of receptor and non-receptor tyrosine kinases control these events by catalyzing the transfer of phosphate from ATP to a tyrosine residue of specific cell protein targets.
- families of receptor and non-receptor tyrosine kinases control these events by catalyzing the transfer of phosphate from ATP to a tyrosine residue of specific cell protein targets.
- kinases in the protein kinase family include, without limitation, abl , Alct, bcr-abl , BIk, Brk, Btk, o-kit, c-Met, c-src, c-fins, CDKl , CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDKlO, cRafl, CSFlR, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFRl , FGFR2, FGFR2, FGFR
- kinase activity acts as molecular switches regulating cell proliferation, activation, and/or differentiation. Uncontrolled or excessive kinase activity has been observed in many disease states including benign and malignant proliferation disorders as well as diseases resulting from inappropriate activation of the immune system (autoimmune disorders), allograft rejection, and graft vs host disease.
- Src kinase is involved in proliferation and migration responses in many cell types, cell activation, adhesion, motility, and survival, growth factor receptor signaling, and osteoclast activation (Biscardi et al,, Adv. Cancer Res. (1999), 76, 61-119; Yeatman et al., Nat. Rev. Cancer (2004), 4, 470-480; Owens, D, W,; McLean et al,, MoI. Biol.
- Src Src
- Fyn Yes, Fgr, Lyn
- HcIc HcIc
- BIk Bolen et al,, Annu. Rev. Immunol, (1997), 15, 371)
- SH4 domain contains the myristylation signals that guide the Src molecule to the cell membrane.
- Src proteins This unique domain of Src proteins is responsible for their specific interaction with particular receptors and protein targets (Thomas et al,, Annu Rev C 6 ll Dev Biol (1997), 13, 513-609), The modulating regions, SH3 and SH2, control intra- as well as intermolecular interactions with protein substrates which affect Src catalytic activity, localisation and association with protein targets (Pawson T,, Nature (1995), 373, 573-580),
- the kinase domain, SHl found in all proteins of the Src family, is responsible for the tyrosine kinase activity and has a central role in binding of substrates,
- the N-terminal half of Src kinase contains the site(s) for its tyrosine phosphorylation and regulates the catalytic activity of Src (Thomas et al., Annu Rev Cell Dev Biol (1997), 13 : 513-609), v-Src differs from cellular Src
- v-Src transforming protein
- RSV Rous sarcoma virus
- c-Src normal cellular protein
- tyrosine kinase activity Collett et al, Proc Natl Acad Sci U S A (1978), 75, 2021- 2024
- This kinase phosphorylates its protein substrates exclusively on tyrosyl residues (Hunter et al,, Proc Natl Acad Sci U S A (1980), 77, 131 1 -1315).
- Src is a cytoplasmic protein tyrosine kinase, whose activation and recruitment to perimembranal signaling complexes has important implications for cellular fate. It has well-documented that Src protein levels and Src kinase activity are significantly elevated in human breast cancers (Muthuswamy et al., Oncogene, (1995), 1 1 , 1801 - 1810); Wang et al,, Oncogene (1999), 18, 1227-1237; Warmuth et al,, Curr, P harm.
- NSCLCs non-small cell lung cancers
- bladder cancer bladder cancer
- oesophageal cancer Janlcowski et al., Gut, (1992), 33, 1033-8
- prostate and ovarian cancer Wiener et al,, Clin, Cancer Research, (1999), 5, 2164-70
- melanoma and sarcoma Bohlen et al., Oncogene, (1993), 8, 2025-2031 ; Tatosyan et al,, Biochemistry (Moscow) (2000), 65, 49-58).
- Src kinase modulates signal transduction through multiple oncogenic pathways, including EGFR, Her2/neu, PDGFR 1 FGFR, and VEGFR (Frame et al., Biochim Biophys Acta (2002), 1602, 1 14-130; Sakamoto et al., Jpn J Cancer Res, (2001), 92: 941 -946), [0009]
- Src kinase inhibitors may be useful anti-cancer agents (Abram et al,, Exp, Cell Res..
- Src kinase inhibitors have also been reported to be effective in an animal model of cerebral ischemia (Paul et al, Nature Medicine, (2001), 7, 222), suggesting that Src kinase inhibitors may be effective at limiting brain damage following stroke, Suppression of arthritic bone destruction has been achieved by the overexpression of CSK in rheumatoid synoviocytes and osteoclasts (Takayanagi et al,, J, Clin. Invest.
- Src-family kinases are also important for signaling downstream of other immune cell receptors. Fyn, like Lck, is involved in TCR signaling in T cells (Appleby et al,, Cell, (1992), 70, 751), HcIc and Fgr are involved in Fc ⁇ receptor signaling leading to neutrophil activation (Vicentini et al,, J, Immunol, (2002), 168, 6446), Lyn and Src also participate in Fc ⁇ receptor signaling leading to release of histamine and other allergic mediators (Turner, H, and Kinet, J-P Nature (1999), 402, B24), These-fmdings suggest that Src family kinase inhibitors may be useful in treating allergic diseases and asthma.
- Other Src family kinases are also potential therapeutic targets, LcIc plays a role in T- cell signaling.
- Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis (Molina et al., Nature, (1992), 357, 161)
- HcIc is a member of the Src protein-tyrosine ldnase family and is expressed strongly in macrophages, an important HIV target cell and its inhibition in HIV-infected macrophages might slow disease progression (Ye et al., Biochemistry, (2004), 43 (50), 15775 -15784)
- HcIc, Fgr and Lyn have been identified as important mediators of integrin signaling in myeloid leukocytes (Lowell et al,, J, Leukoc, Biol , (1999), 65, 313), Inhibition of these kinase mediators may therefore be useful
- SyIc is a tyrosine kinase that plays a critical role in the cell degranulation and eosinophil actuation and SyIc kinase is implicated in various allergic disorders, in particular asthma (Taylor et al,, MoI. Cell. Biol (1995), 15, 4149).
- BCR-ABL encodes the BCR-AEL protein, a constitutively active cytoplasmic tyrosine kinase present in 90% of all patients with chronic myelogenous leukemia (CML) and in 15-30% of adult patients with acute lymphoblastic leukemia (ALL), Numerous studies have demonstrated that the activity of BCR-ABL is required for the cancer causing ability of this chimeric protein,
- Src ldnases play a role in the replication of hepatitis B virus.
- the virally encoded transcription factor HBx activates Src in a step required for propagation of the virus (Klein et al,, EMBO J. (1999), 18, 5019; Klein et al., MoI. Cell Biol.
- src family ldnases participate in signal transduction in several cell types, For example, fyn, like IcIc, is involved in T-cell activation, HcIc and fgr are involved in Fe gamma receptor mediated oxidative burst of neutrophils. Src and lyn are believed to be important in Fc epsilon induced degranulation of mast cells, and so may play a role in asthma and other allergic diseases, The kinase lyn is known to be involved in the cellular response to DNA damage induced by UV light (Hiwasa et al,, FEBS Lett.
- Inhibitors of lyn ldnase may thus be useful as potentiators in radiation therapy,
- T cells play a pivotal role in the regulation of immune responses and are important for establishing immunity to pathogens.
- T cells are often activated during inflammatory autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, type I diabetes, multiple sclerosis, Sjogren's disease, myasthenia gravis, psoriasis, and lupus, T cell activation is also an important component of transplant rejection, allergic reactions, and asthma.
- T cells are activated by specific antigens through the T cell receptor, which is expressed on the cell surface, This activation triggers a series of intracellular signaling cascades mediated by enzymes expressed within the cell (Kane et al. Current Opinion in Immunol.
- IL-2 interleukin-2
- IL-2 is a necessary cytokine in T cell activation, leading to proliferation and amplification of specific immune responses
- 6,440,965 disclosed substituted pyrimidine derivatives in the treatment of neurodegenerative or neurological disorders
- PCT WO 02/08205 reported the pyrimidine derivatives having neurotrophic activity
- PCT WO 03/014111 disclosed arylpiperazines and arylpiperi dines and their use as metalloproteinase inhibiting agents
- PCT WO 03/024448 described compounds as inhibitors of histone deacetylase enzymatic activity
- PCT WO 04/058776 disclosed compounds which possess anti-angiogenic activity
- PCT WO 01/94341 and WO 02/16352 disclosed Src ldnase inhibitors of quinazoline derivatives
- PCT WO03/026666Aland WO03/018021A1 disclosed pyrimidinyl derivatives as kinase inhibitors.
- an antitumor agent comprising a triazine derivative as described in formula (I), pharmaceutically-acceptable formulations thereof, methods for making novel compounds and and methods and compositions for using the compounds.
- the compounds and compositions comprising the compounds in formula (I) have utility in treatment of a variety of diseases.
- combination therapy described herein may be provided by the preparation of the triazine derivative of formula (I) and the other therapeutic agent as separate pharmaceutical formulations followed by the administration thereof to a patient simultaneously, semi- simultaneously, separately or over regular intervals,
- the present invention provides methods of use for certain chemical compounds such as ldnase inhibitors for treatment of various diseases, disorders, and pathologies, for example, cancer, and vascular disorders, such as myocardial infarction (MI), stroke, or ischemia.
- the triazine compounds described in this invention may block the enzymatic activity of some or many of the members of the Src family, in addition to blocking the activity of other receptor and non-receptor kineses.
- Such compounds may be beneficial for treatment of the diseases where disorders affect cell motility, adhesion, and cell cycle progression, and in addition, diseases with related hypoxic conditions, osteoporosis and conditions, which result from or are related to increases in vascular permeability, inflammation or respiratory distress, tumor growth, invasion, angiogenesis, metastases and apoptosis, [0026]
- methods for modulating Src-family kinase activity comprising contacting the kinase with a compound of formula 1 in an amount sufficient to modulate the activity of the kinase, In some variation the activity of the kinase is reduced. In some variation the activity is inhibited.
- Rl represents hydrogen, halogen, hydroxy, amino, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, arylalkyl, heterocyclic, heteroaryl, heterocycloalkyl, alkylsulfonyl, alkoxycarbonyl and alkylcarbonyl, [0029] R2 is selected from:
- R 3 is hydrogen, C 1 -C 4 alkyl, oxo;
- R 4 is chosen from: (a) hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C1 0 aryl or heteroaryl, (C 3 -C 7 cycloalkyl) C 1 -C 4 alkyl, C 1 - C 6 haloalkyl, C 1 -C 6 allcoxy, C 1 - C 6 alkylthio, C 2 - C 6 alkanoyl, C 1 - C 6 alkoxycarbonyl, C 2 - C 6 alkanoyloxy, mono- and di-(C 3 -C 8 cycloalkyl)aminoCo-C4alkyl, (4- to 7- membered heterocycle)Co-C4alkyl, C 1 -C 6 alkylsulfonyl, mono- and di-( C 1 - C 6 alkyl) sulfonamido, and mono- and di-(
- Ar 1 , and Ar 2 independently are a heteroaryl or aryl, each of which is substituted with from 0 to 4 substituents independently chosen from:
- each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently at each occurrence.
- halo or halogen refers to fluorine, chlorine, bromine or iodine.
- alkyl herein alone or as part of another group refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 12 carbon atoms unless otherwise defined. Alkyl groups may be substituted at any available point of attachment. An alkyl group substituted with another alkyl group is also referred to as a "branched alkyl group”.
- Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, dimethylpentyl, octyl. 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
- substituents include but are not limited to one or more of the following groups: alkyl, aryl, halo (such as F, Cl, Br, I), haloalkyl (such as CCI3 or CF3), alkoxy, alkylthio, hydroxy, carboxy (-COOH), alkyloxycarbonyl (-C(O)R), alkylcarbonyloxy (- OCOR), amino (- NH2), carbamoyl (-NHCOOR- or -OCONHR-), urea (-NHC0NHR-) or thiol (-SH).
- alkyl groups are substituted with, for example, amino, heterocycloalkyl, such as morpholine, piperazine, piperidine, azetidine, hydroxyl, methoxy, or heteroaryl groups such as pyrrolidine.
- amino, heterocycloalkyl such as morpholine, piperazine, piperidine, azetidine, hydroxyl, methoxy, or heteroaryl groups such as pyrrolidine.
- 'cycloalkyl herein alone or as pail of another group refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms, The examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and like, Further, a cycloalkyl may be substituted.
- alkenyl herein alone or as part of another group refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon double bond.
- groups include the vinyl, allyl, 1-propenyl, isopropenyl, 2 -methyl- 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1 -pentenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1 -heptenyl, and like, Alkenyl groups may also be substituted at any available point of attachment, Exemplary substituents for alkenyl groups include those listed above for alkyl groups, and especially include C3 to C7 cycloalkyl groups such as cyclopropyl, cyclopentyl and
- alkynyl refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond
- Alkynyl groups include C2-C8 alkynyl, C2-C6 alkynyl and C2-C4 alkynyl groups, which have from 2 to
- alkynyl group examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl.
- Alkynyl groups may also be substituted at any available point of attachment, Exemplary substituents for alkynyl groups include those listed above for alkyl groups such as amino, alkylamino, etc, The numbers in the subscript after the symbol "C" define the number of carbon atoms a particular group can contain.
- alkoxy alone or as part of another group denotes an alkyl group as described above bonded through an oxygen linkage (-O-).
- Preferred alkoxy groups have from 1 to 8 carbon atoms, Examples of such groups include the methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n- hexyloxy, cyclohexyloxy, n-heptyloxy, n-octyloxy and 2-ethylhexyloxy.
- alkylthio refers to an alkyl group as described above attached via a sulfur bridge
- Preferred alkoxy and alkylthio groups are those in which an alkyl group is attached via the heteroatom bridge
- Preferred alkylthio groups have from 1 to 8 carbon atoms. Examples of such groups include the methylthio, ethylthio, n-propythiol, n-butylthiol, and like,
- alkoxycarbonyl herein alone or as part of another group denotes an alkoxy group bonded through a carbonyl group.
- An alkoxycarbonyl radical is represented by the formula: -C(O)OR, where the R group is a straight or branched C1-C6 alkyl group, cycloalkyl, aryl, or heteroaryl.
- alkylcarbonyl herein alone or as part of another group refers to an alkyl group bonded through a carbonyl group or -C(O)R.
- arylalkyl herein alone or as part of another group denotes an aromatic ring bonded through an alkyl group (such as benzyl) as described above,
- aryl herein alone or as part of another group refers to monocyclic or bicyclic aromatic rings, e g, phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., napthyl, phenanthrenyl and the like, An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 20 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
- halogen such as I, Br, F, or Cl
- alkyl such as methyl, ethyl, propyl, alkoxy, such as methoxy or ethoxy, hydroxy, carboxy, carbamoyl, alkyloxycarbonyl, niti'o, alkenyloxy, trifluoromethyl, amino, cycloalkyl, aryl, heteroaryl,
- amino herein alone or as part of another group refers to -NH2.
- An “amino” may optionally be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, alkenyl, alkynyl, heteroaryl, heteroaryl alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, carbonyl or carboxyl.
- substituents may be further substituted with a carboxylic acid, any of the alkyl or aryl substituents set out herein.
- the amino groups are substituted with carboxyl or carbonyl to form N-acyl or N-carbamoyl derivatives.
- alkylsulfonyl refers to groups of the formula (SO2)-alkyl, in which the sulfur atom is the point of attachment.
- alkylsulfonyl groups include Cl- C6 alkylsulfonyl groups, which have from 1 to 6 carbon atoms.
- Methylsulfonyl is one representative alkylsulfonyl group,
- heteroatom refers to any atom other than carbon, for example, N, O, or S
- heteroaryl herein alone or as part of another group refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings.
- Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom,
- the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
- the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized,
- Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non- aromatic.
- the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
- heteroaryl groups include acridinyl, azopanyl, azocinyl, benzimidazolyl, benzimidazolinyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolylcarbazolyl, benztetrazolyl, NH- carbazolyl, carbolinyl, chromanyl, clirornenyl, cinnolinyl, decahydroquinolinyl, tetrahydrofuran, dihydroisoquinolinyl, dihydrotetrahydrofuranyl, 1 ,4- dioxa-8-aza-spirodec-8-yl, dithiazinyl, furanyl, furazanyl, imidazolinyl, imidazolidinyl, dithia
- heterocycle or “heterocycloalkyl” herein alone or as part of another group refers to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N.
- the "heterocycle” has from 1 to 3 fused, pendant or spiro rings, at least one of which is a heterocyclic ring (i.e.
- the heterocyclic ring may be optionally substituted which means that the heterocyclic ring may be substituted at one or more substitutable ring positions by one or more groups independently selected from alkyl (preferably lower alkyl), heterocycloalkyl, heteroaryl, alkoxy (preferably lower allcoxy), nitro, mono alkyl ami no (preferably a lower alkylamino), dialkylamino (preferably a alkylamino), cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy; lower alkyl), alkoxycarbonyl (preferably a lower alkoxycarbonyl), alkylcarbonyloxy (preferably a lower alkyl), alkylcarbonyloxy (preferably a lower alkyl), alkylcarbonyloxy (preferably
- a heterocyclic group may generally be linked via any ring or substituent atom, provided that a stable compound results, N-linked heterocyclic groups are linked via a component nitrogen atom.
- a heterocyclic ring comprises 1 -4 heteroatoms; within certain embodiments each heterocyclic ring has 1 or 2 heteroatoms per ring.
- Each heterocyclic ring generally contains from 3 to 8 ring members (rings having from to 7 ring members are recited in certain embodiments), and heterocycles comprising fused, pendant or spiro rings typically contain from 9 to 14 ring members which consists of carbon atoms and contains one, two, or three heteroatoms selected from nitrogen, oxygen and/or sulfur.
- heterocycle or “heterocycloalkyl groups include piperazine, piperidine, morpholine, thiomorpholine, pyrrolidine, imidazolidine and thiazolide.
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above,
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above.
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above.
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above.
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above.
- substituteduent refers to a molecular moiety that is
- a "ring substituent” may be a moiety such as a halogen, alkyl group, haloalkyl group or other group discussed herein that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member.
- heteroaryl or heterocyclyl group may be substituted at one or more substitutable ring positions by one or more groups independently selected from alkyl (preferably lower alkyl), alkoxy (preferably lower alkoxy), nitro, monoalkylamino (preferably with one to six carbons), dialkylamino (preferably with one to six carbons), cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy and lower alkyl), alkoxycarbonyl (preferably a lower alkoxycarbonyl), alkylcarbonyloxy (preferably a lower alkylcarbonyloxy) and aryl (preferably phenyl), said aryl being optionally substituted by halo, lower alkyl and lower
- kinase refers to any enzyme that catalyzes the addition of phosphate groups to a protein residue; for example, serine and threonine kineses catalyze the addition of phosphate groups to serine and threonine residues
- the terms "Src kinase,” “Src kinase family,” and “Src family” refer to the related homologs or analogs belonging to the mammalian family of Src kineses, including, for example, c-Src, Fyn, Yes and Lyn ldneses and the hematopoietic-restricted kineses HcIc, Fgr, LcIc and BIk.
- the term "therapeutically effective amount” refers to the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, e.g., restoration or maintenance of vasculostasis or prevention of the compromise or loss or vasculostasis; reduction of tumor burden; reduction of morbidity and/or mortality, [0067]
- the term 'pharmaceutically acceptable refers to the fact that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- administering a compound refers to the act of providing a compound of the invention or pharmaceutical composition to the subject in need of treatment
- protected refers that the group is in modified form to preclude undesired side reactions at the protected site.
- Suitable protecting groups for the compounds of the present invention will be recognized from the present application talcing into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T, W, et al,, Protective Groups in Organic Synthesis, John Wiley & Sons, New York (1999).
- the te ⁇ n "pharmaceutically acceptable salt” of a compound recited herein is an acid or base salt that is suitable for use in contact with the tissues of human beings or animals without excessive toxicity or carcinogenicity, and preferably without irritation, allergic response, or other problem or complication
- Such salts include mineral and organic acid salts of basic residues such as amines, as well as alkali or organic salts of acidic residues such as carboxylic acids
- Specific pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzene sulfonic, ethane disulfonic, 2- hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic,
- a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method, Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, the use of nonaqueous media, such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile, is preferred.
- nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile
- each compound of Formula I may, but need not, be formulated as a hydrate, solvate or non- covalent complex,
- the various crystal forms and polymorphs are within the scope of the present invention.
- prodrugs of the compounds of Formula I are also provided herein.
- prodrug refers a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified in vivo, following administration to a patient, to produce a compound of Formula I, or other formula provided herein.
- a prodrug may be an acylated derivative of a compound as provided herein.
- Prodrugs include compounds wherein hydroxy, amine or thiol groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy, amino, or thiol group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein.
- Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved in vivo to yield the parent compounds,
- Groups that are "optionally substituted” are unsubstituted or are substituted by other than hydrogen at one or more available positions, Such optional substituents include, for example, hydroxy, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, C1-C6 alkoxy, C2-C6 alkyl ether, C3-C6 alkanone, C2-C6 alkylthio, amino, mono- or di-(Cl-C6 alkyl)amino, C1-C6 haloalkyl, -COOH, -CONH2, mono- or di-(Cl-C6 alkyl)arninocarbonyl, - SO2NH2, and/or mono or di(Cl-C6 alkyl) sulfonamido, as well as carbocyclic and heterocyclic groups.
- optional substituents include, for example, hydroxy, halogen, cyano,
- Rl groups of formula I are list below: -CH3, -CN, -CF3 ; -CH2CH3, -Ph 5 -PhCl, -PhOMe,
- Preferred R2 groups of formula I are list below:
- the compounds of the invention may be compounds of formula (I) wherein Rl is selected from amino, cyano, C1-C6 alkyl, C-C6alkoxy, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl C2-C6 alkanoyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, mono- and di- (C1- C6alkyl)amino, C1-C6 alkylsulfonyl, mono- and di-(C1-C6alkyl) sulfonamido and mono- and di-(C1-C6alkyl)aminocarbonyl;
- R2 is selected from:
- X is CH, when R4 is hydrogen; or X-R4 is O; or X is N when R4 represents groups, [0080] R3 is hydrogen, C1-C4 alkyl, oxo;
- R4 is chosen from: (a) hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaiyl, (C3-C7cycloalkyl)C1-C4alkyl, Cl - C6 haloalkyl, C1-C6 alkoxy, Cl- C6 alkylthio, C2-C6 alkanoyl, Cl- C6 alkoxycarbonyl, C2- C6 alkanoyloxy, mono- and di-(C3-C8 cycloalkyl)aminoC0-C4alkyl, (4- to 7- membered heterocycle)C0-C4alkyl, C1 -C6 alkylsulfonyl, mono- and di-(Cl- C6 alkyl) sulfonamido, and mono- and di-(Cl-C6alkyl)arninocarbonyl, each of which is substitute
- Ar1 and Ar2 are independently a heteroaryl or aryl, each of which is substituted with from O to 4 substituents independently chosen from:
- the compounds of the invention may be compounds of formula (I) wherein
- Rl is selected from cyano, C1-C6 alkyl, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 aryl;
- R2 is selected from a heterocyclic, herteroaryl or groups of the formula (Ia):
- X is CH, when R4 is hydrogen; X is N for other R4 groups.
- R3 is hydrogen, C1-C4 alkyl, oxo
- R4 is chosen from; C3-C10 aryl or heteroaryl, (C3-C7cycloalIcyl)Cl-C4alkyl, mono- and di-(C3-C8 cycloalkyl)aminoC0-C4alkyl, (4- to 7- membered heterocycle)C0-C4alkyl, C1 -C6 alkylsulfonyl, mono- and di-(Cl - C6 alkyl) sulfonamide;
- ArI and Ar2 are independently a heteroaryl or aryl, each of which is substituted with from 0 to 4 substituents independently chosen from;
- R4 is (CH2)nY, n is integer 0 to 4, Y is selected from morpholin-4- yl, thiomorpholin-4-yl, pyridinyl, pirimidinyl, piperidinyl, piperazinyl, or pyrrolidinyl, [0085] According to one embodiment, the present invention relates to a compound of formula I wherein ArI is thioazolyl.
- the present invention relates to a compound of formula I wherein ArI is pyridyl
- the present invention relates to a compound of formula I wherein ArI is pyrimidinyl
- the present invention relates to a compound of formula I wherein ArI is pyrazinyl.
- the present invention relates to a compound of formula I wherein ArI is imidazolyl
- the present invention relates to a compound of formula I wherein ArI is benzothioazolyl,
- the present invention relates to a compound of formula I wherein ArI is benzo[l ,2,4]triazinyl,
- the present invention relates to a compound of formula I wherein ArI is phenyl.
- the present invention relates to a compound of formula I wherein Ar2 is 2-methyl-6-chloro-phenyl.
- the present invention relates to a compound of formula I wherein Ar2 is 2,6-dichlorophenyl.
- the present invention relates to a compound of formula I wherein Ar2 is 2,6-dimethylphenyl,
- the present invention relates to a compound of formula I wherein Rl is methyl.
- the present invention relates to a compound of formula I wherein Rl is ethyl.
- the present invention relates to a compound of formula I wherein Rl is trifloromethyl.
- the present invention relates to a compound of formula I wherein Rl is CN,
- the present invention relates to a compound of formula I wheiein Rl is phenyl
- the present invention relates to a compound of formula I wherein L is oxygen.
- the present invention relates to a compound of formula I wherein L is CO,
- the present invention relates to a compound of formula I wherein L is NHCO.
- the present invention relates to a compound of formula I wherein L is CONH,
- the present invention relates to a compound of formula I wherein L is NH.
- the present invention relates to a compound of formula I wherein L is S,
- the present invention relates to a compound of formula I wherein L is SO,
- the present invention relates to a compound of formula I wherein L is SO2,
- the present invention relates to a compound of formula I wherein Ar2-L-Arl-NH2 is:
- Examples of specific compounds of the present invention are those compounds defined in the following:
- a method of preparing the inventive compounds is provided,
- the compounds of the present invention can be generally prepared using cyanuric chloride as a stalling material.
- Compound (I) may contain various stereoisomers, geometric isomers, tautomeric isomers, and the like. All of possible isomers and their mixtures are included in the present invention, and the mixing ratio is not particularly limited.
- the triazine derivative compounds of Formula (I) in this invention can be prepared by known procedure in the prior art. The examples could be found in US patent No. 2005250945 Al; US patent No. 20050227983 Al ; PCT WO 05/007646A1 ; PCT WO 05/007648A2; PCT WO 05/003103A2; PCT WO 05/011703 Al; and J. of Med. Chem. (2004), 47(19), 4649-4652, Starting materials are commercially available from suppliers such as Sigma- Aldrich Corp.
- reduction refers to the process of reducing a nitro functionality to an amino functionality, or the process of transforming an ester functionality to an alcohol
- the reduction of a nitro group can be carried out in a number of ways well known to those-tskilled in the art of organic synthesis including, but not limited to, catalytic hydrogenation, reduction with SnCI2 and reduction with titanium bichloride,
- the reduction of an ester group is typically performed using metal hydride reagents including, but not limited to, diisobutyl-aluminum hydride (DIBAL), lithium aluminum hydride (LAH), and sodium borohydride.
- DIBAL diisobutyl-aluminum hydride
- LAH lithium aluminum hydride
- sodium borohydride sodium borohydride
- hydrolyze refers to the reaction of a substrate or reactant with water. More specifically, “hydrolyze” refers to the conversion of an ester or nitrite functionality into a carboxylic acid. This process can be catalyzed by a variety of acids or bases well known to those skilled in the art of organic synthesis.
- the compounds of Formula I may be prepared by use of known chemical reactions and procedures, The following general preparative methods are presented to aid one of skill in the art in synthesizing the inhibitors,, with more detailed examples being presented in the experimental section describing the working examples,
- Heterocyclic amines are defined in formula II, .wherein Ar 1 is heteroaryl. Some of heterocyclic amines are commercially available, others may be prepared by known procedure in the prior art (e.g., U.S. Patent 2006/0004067 Al ; J, Med, Chem, 2004, 47, 6658-6661 ; World patent No. WO 99/32106; Katritzky, et al, Comprehensive Heterocyclic Chemistry; Permagon Press: Oxford, UK, 1984, March. Advanced Organic Chemistry, 3 " Ed.; John Wiley: New York, 1985).
- 2-amino-N-(substituted aryl) thiazole-5-carboxamide (B) are available by the reaction of thiourea with a substituted phenyl-3-ethoxyacrylamide (A) in the presence of NBS, as illustrated in Scheme 1 .
- Compound B in turn, can be made from the reaction of 3- ethyoxyacryloyl chloride with an substituted aniline Ar 2 -NH 2 Scheme 1
- Substituted anilines may be generated using standard methods (March, J,, Advanced Organic Chemistry, 4 th Ed., John Wiley, New York (1992); Larock, R., Comprehensive Organic Transformations; John Wiley, New York (1999); PCT WO 99/32106).
- aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H 2 Oi- a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride, Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH, or using a zero valent metal, such as Fe, Sri or Ca, often in acidic media. Many methods exist for the synthesis of nitroaryls,
- Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO 3 , or an alternative NOj + source. Nitroaryls may be further elaborated prior to reduction,
- nitroaryls substituted with potential leaving groups may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme 3) or phenoxide, Nitroaryls may also undergo Ullman-type coupling reactions (Scheme 3).
- triazine derivatives can be formed from the reaction of a 6- alkyl or aryl substituted dichloro-triazine with an aryl amine (Ar2-L-Arl -NH2), followed by reaction with a substituted amine (HNR 3 R b ).
- the 6-alkyl or aryl substituted dichloro-triazine may be synthesized by the methods known in the art (e.g., J, Med.
- Triazine derivatives also can be generated from the reaction of a substituted amine '(HNR 9 R b ), followed by reaction with an aryl amine (Ai'2-L-Ari-NH2).
- the triazine derivative can also be synthesized by the reaction of cyanuric chloride with a sequence of two different amines to give2,4-disubstituted-6-chloro- 1,3,5-triazines.
- the displacement of the last chlorine by amine, hydrazine, hydroxyl or other nucleophilio group can be achieved by increasing the temperature, affording the trisubstituted- 1 ,3,5-triazines, Scheme 5
- the reaction is preferably conducted in the presence of an inert solvent, There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent.
- suitable solvents include: aliphatic hydrocarbons, such as hexane, heptane, ligroin and petroleum ether; aromatic hydrocarbons, such as benzene, toluene and xylene; halogenated hydrocarbons, especially aromatic and aliphatic hydrocarbons, such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene and the dichlorobenzenes; esters, such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate and diethyl carbonate; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane and diethylene glycol dimethyl ether; ketones, such as acetone, methyl ethyl ketone, methyl isobutyl ketone, isophor
- the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention, In general, we find it convenient to carry out the reaction at a temperature of from -50°C to 100°C, [0126]
- the present invention provides compositions of matter that are formulations of one or more active drugs and a pharmaceutically-acceptable carrier, In this regard, the invention provides a composition for administration to a mammalian subject . which may include a compound of formula I, or its Pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases, Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate.
- compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques, Preferably, the compositions are administered orally, intraperitoneal ⁇ or intravenously.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, troches, elixirs, suspensions, syrups, wafers, chewing gums, aqueous suspensions or solutions.
- the oral compositions may contain additional ingredients such as: a binder such ⁇ as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such 1 as starch or lactose, a disintegrating agent such as alginic acid, com starch and the like; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin or flavoring agent such as peppermint, methyl salicylate, or orange flavoring,
- a binder such ⁇ as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such 1 as starch or lactose, a disintegrating agent such as alginic acid, com starch and the like
- a lubricant such as magnesium stearate
- a glidant such as colloidal silicon dioxide
- a sweetening agent such as sucrose or saccharin or flavoring agent such as peppermint, methyl salicylate
- tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
- a syrup may contain, in addition to the active ingredients, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors, Materials used in preparing these various compositions should be pharmaceutically or veterinarally pure and non-toxic in the amounts used.
- the active ingredient may . be incorporated into a solution or suspension
- the solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- the pharmaceutical forms suitable for injectable use include sterile solutions, dispersions, emulsions, and sterile powders.
- the final form should be stable under conditions of manufacture and storage. Furthermore, the final pharmaceutical form should be protected against contamination and should, therefore, be able to inhibit the growth of microorganisms such as bacteria or fungi.
- a single intravenous or intraperitoneal dose can be administered. Alternatively, a slow long-term infusion or multiple short-term daily infusions may be utilized, typically lasting from 1 to 8 days, Alternate day dosing or dosing once every several days may also be utilized,
- Sterile, injectable solutions may be prepared by incorporating a compound in the required amount into one or more appropriate solvents to which other ingredients; listed above or known to those skilled in the art, may be added as required, Sterile injectable solutions may be prepared by incorporating the compound in the required amount in the appropriate solvent with various other ingredients as required, Sterilizing procedures, such as filtration, may then follow, Typically, dispersions are made by incorporating the compound into a sterile vehicle which also contains the dispersion medium and the required other ingredients as indicated above, In the case of a sterile powder, the preferred methods include vacuum drying or freeze drying to which any required ingredients are added,
- Suitable pharmaceutical earners include sterile water; saline, dextrose; dextrose in water or saline; condensation products of castor oil and ethylene oxide combining about 30 to about 35 moles of ethylene oxide per mole of castor oil; liquid acid; lower alkanols; oils such as com oil; peanut oil, sesame oil and the like, with emulsifiers such as mono- or di-glyceride of a fatty acid, or a phosphatide, e.g., lecithin, and the like; glycols; polyalkylene glycols; aqueous media in the presence of a suspending agent, for example, sodium carboxymethylcellulose; sodium alginate; poly(vinylpy ⁇ olidone) ; and the like, alone, or with suitable dispensing agents such as lecithin; polyoxyethylene stearate; and the like,
- the earner may also contain adjuvants such as preserving stabilizing, wetting, emulsifying
- United States Patent Nos. 5,916,596, 6,506,405 and 6,537,579 teach the preparation of nanoparticles from the biocompatible polymers, such as albumin.
- methods for the formation of nanoparticles of the present invention by a solvent evaporation technique from an oil-in-water emulsion prepared under conditions of high shear forces (e.g., sonication, high pressure homogenization, or the like).
- compositions of this invention may be administered in the form of suppositories for rectal administration, These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug, Such materials include cocoa butter, beeswax and polyethylene glycols, [0138]
- suppositories for rectal administration These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug, Such materials include cocoa butter, beeswax and polyethylene glycols,
- the pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application; including diseases of the eye. the sldn, or the lower intestinal tract.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used
- the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
- Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water,
- the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers, Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water,
- the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
- the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents,
- compositions of this invention are formulated for oral administration.
- the compounds of the invention may be used to treat diseases associated with cellular proliferation or hyperproliferation, such as cancers which include but are not limited to tumors of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas.
- diseases associated with cellular proliferation or hyperproliferation such as cancers which include but are not limited to tumors of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas.
- the compounds of the invention may also be used to treat cancers of the liver and biliary tree (particularly hepatocellular carcinoma), intestinal cancers, particularly colorectal cancer, ovarian cancer, small cell and non-small cell lung cancer, breast cancer, sarcomas (including fibrosarcoma, malignant fibrous histiocytoma, embryonal rhabdomysocarcoma, leiomysosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and alveolar soft part sarcoma), neoplasms of the central nervous systems (particularly brain cancer), and lymphomas (including Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burldtt's lymphoma,
- the compounds and methods of the present invention are also useful in treating a variety of disorders, including but not limited to, for example: stroke, cardiovascular disease, myocardial infarction, congestive heart failure, cardiomyopathy, myocarditis, ischemic heart disease, coronary artery disease, cardiogenic shock, vascular shock, pulmonary hypertension, pulmonary edema (including cardiogenic pulmonary edema), pleural effusions, rheumatoid arthritis, diabetic retinopathy, retinitis pigmentosa, and retinopathies, including diabetic retinopathy and retinopathy of prematurity, inflammatory diseases, restenosis, asthma, acute or adult respiratory distress syndrome (ARDS), lupus, vascular leakage, protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, transplantation tolerance induction;
- agents e.g., chemotherapeutic agents or protein therapeutic agents described below
- T- cell mediated hypersensitivity diseases including contact hypersensitivity, delayed- type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); Type 1 diabetes; psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' disease; Addison's disease (autoimmune disease of the adrenal glands); autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituitarism; Guillain-Barre syndrome; other autoimmune diseases; cancers, including those where ldneses such as Src-family kineses are activated or overexpressed, such as colon carcinoma and thymoma, or cancers where ldnase activity facilitates tumor growth or survival; glomerulonephritis, serum sickness; uticaria; allergic diseases
- the compounds of the invention may be used to treat diseases associated with undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of formula 1 , wherein the disease or condition is associated with a ldnase,
- the compounds of the invention may be used to treat diseases associated with undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of formula 1 , wherein the disease or condition is associated with a tyrosine kinase,
- the compounds of the invention may be used to treat diseases associated with undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of formula 1 , wherein the disease or condition is associated with the kinase that is a serine kinase or a threonine kinase, [0149]
- the compounds of the invention may be used to treat diseases associated with undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of formula 1, wherein the disease or condition is associated with the kinase that is a Src family l ⁇ nase.
- the invention also provides methods of treating a mammal afflicted with the above diseases and conditions,
- the amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
- compositions should be formulated so that a dosage of between 0.01-100 mg/lcg body weight/day of the inhibitor can be administered to a patient receiving these compositions, [0151]
- the invention compounds are administered in combination with chemotherapeutic agent, an anti-inflammatory agent, antihistamines, chemotherapeutic agent, immunomodulator, therapeutic antibody or a protein kinase inhibitor, e.g., a tyrosine ldnase inhibitor, to a subject in need of such treatment,
- the method includes administering one or more of the inventive compounds to the afflicted mammal,
- the method may further include the administration of a second active agent, such as a cytotoxic agent, including alkylating agents, tumor necrosis factors, intercalators, microrubulin inhibitors, and topoisomerase inhibitors
- a second active agent such as a cytotoxic agent, including alkylating agents, tumor necrosis factors, intercalators, microrubulin inhibitors, and topoisomerase inhibitors
- the second active agent may be coadministered in the same composition or in a second composition
- suitable second active agents include, but are not limited to, a cytotoxic drug such as Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin
- the compounds and compositions may be used at sub-cytotoxic levels in combination with other agents in order to achieve highly selective activity in the treatment of non-neoplastic disorders, such as heart disease, stroke and neurodegenerative diseases ( ⁇ Vhitesell et al., Curr Cancer Drug Targets (2003), 3(5), 349-58).
- the exemplary therapeutical agents that may be administered in combination with invention compounds include EGFR inhibitors, such as gefitinib, erlotinib, and cetuximab.
- Her2 inhibitors include canertinib, EKB-569, and GW-572016.
- Src inhibitors include Src inhibitors, dasatinib, as well as Casodex (bicalutami.de), Tamoxifen, MEK-I kinase inhibitors, MARIC kinase inhibitors, PI3 inhibitors, and PDGF inhibitors, such as imatinib, Hsp90 inhibitors, such as 17-AA G and 17-DMAG
- anti-angiogenic and antivascular agents which, by intemrpting blood flow to solid tumors, render cancer cells quiescent by depriving them of nutrition, Castration, which also renders androgen dependent carcinomas non-proliferative, may also be utilized.
- IGFlR inhibitors inhibitors of non- receptor and receptor tyrosine kineses, and inhibitors of integrin,
- the pharmaceutical composition and method of the present invention may further combine other protein therapeutic agents such as cytokines, immunomodulatory agents and antibodies.
- cytokine encompasses chemoldnes, interleukins, lympholdnes, monokines, colony stimulating factors, and receptor associated proteins, and functional fragments thereof
- functional fragment refers to a polypeptide or peptide which possesses biological function or activity that is identified through a defined functional assay.
- the cytokines include endothelial monocyte activating polypeptide II (EMAP- II), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G- CSF), macrophage- CSF (M-CSF), IL-I, IL-2, IL-3, IL- 4, IL-5, IL-6, IL- 12, and IL-13, interferons, and the like and which is associated with a particular biologic, morphologic, or phenotypic alteration in a cell or cell mechanism,
- EMP- II endothelial monocyte activating polypeptide II
- GM-CSF granulocyte-macrophage-CSF
- G- CSF granulocyte-CSF
- M-CSF macrophage- CSF
- IL-I IL-2, IL-3, IL- 4, IL-5, IL-6, IL- 12, and IL-13, interferons, and the like and which is associated with
- cyclosporins e,g,, cyclosporin A
- CTLA4-Ig antibodies such as ICAM-3, anti-IL-2 receptor (Anti-Tac), anti- CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4 : anti-CD80, anti-CD86
- agents blocking the interaction between CD40 and gp39 such as antibodies specific for CD40 and for gpn39 (i.e., CD154), fusion proteins constructed from CD40 and gp39 (CD40Ig and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG), cholesterol biosynthesis inhibitors such as HM: G CoA reductase inhibitors (lovastatin and simvastatin), non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen and cyclooxygenase inliibitors such as
- NSAIDs non-steroidal antiinflammatory drugs
- NMR spectra IH Nuclear magnetic resonance spectra were recorded at 500 MHz.
- This example illustrated Src Kinase Assays of Compound 5 (referred to Boschelli et al,, J. Med. Chem,; 2004; 47(7) pp 1599 - 1601).
- Brifely To establish the appropriate enzyme concentration for inhibition assays, Src kinase (Upstate Cat ⁇ 14-326, Lot 28234AU) was titrated and incubated with 25 ⁇ M Srctide peptide substrate (KVEKIGEGTYGVVY, where the tyrosine in bold designates the phosphorylated amino acid) and 50 ⁇ M ATP for 60 minutes at 30 °C , The phosphorylated product was detected using the HitHunter p34cdc2 EFC kinase assay (DiscoveRx, Product Code 90-0062, Lot 06G2408),
- Inhibitor IC50 values were determined by titration of compound at the optimal kinase concentration (Kinase EC50), Identical assay conditions were used as above and the effect of compound on kinase activity determined with the HitHunter EFC ldnase assay (DiscoveRx).
- Viability Assay Briefly, cells (5000 cells/well) were plated onto 96-well microtiter plates in RPMI 1640 medium supplemented with 10% FBS and incubated at 37° C. in a humidified 5% CO 2 atmosphere, After 24 hrs, cells were exposed to various concentrations of compound in DMSO and cultured for another 72 hrs. 100 ul of media were removed and 20ul of Promega CellTiter Blue reagent were added to each well and shaken to mix.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007333925A AU2007333925B2 (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
EP07865684A EP2120964A2 (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
CN2007800498388A CN101583365B (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
CA2672893A CA2672893C (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
JP2009541616A JP5622393B2 (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutic applications |
EP15162488.9A EP2923703B1 (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87505706P | 2006-12-15 | 2006-12-15 | |
US60/875,057 | 2006-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008076883A2 true WO2008076883A2 (en) | 2008-06-26 |
WO2008076883A3 WO2008076883A3 (en) | 2008-10-16 |
Family
ID=39168056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/087576 WO2008076883A2 (en) | 2006-12-15 | 2007-12-14 | Triazine derivatives and their therapeutical applications |
Country Status (8)
Country | Link |
---|---|
US (2) | US7858782B2 (en) |
EP (3) | EP2923703B1 (en) |
JP (2) | JP5622393B2 (en) |
CN (1) | CN101583365B (en) |
AU (1) | AU2007333925B2 (en) |
CA (1) | CA2672893C (en) |
ES (1) | ES2699585T3 (en) |
WO (1) | WO2008076883A2 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010144550A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
WO2010144522A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
EP2440051A1 (en) * | 2009-06-08 | 2012-04-18 | Abraxis BioScience, LLC | Triazine derivatives and their therapeutical applications |
JP2012529517A (en) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Benzyl-substituted triazine derivatives and their therapeutic applications |
JP2012529513A (en) * | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Triazine derivatives and their therapeutic applications |
WO2013133367A1 (en) * | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | Novel triazine derivative |
AU2010259002B2 (en) * | 2009-06-08 | 2014-03-20 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
WO2014102759A2 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Process for the preparation of dasatinib and its intermediates |
WO2015003640A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9434979B2 (en) | 2009-10-21 | 2016-09-06 | Shin-San Michael Su | Methods and compositions for cell-proliferation-related disorders |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9512107B2 (en) | 2012-01-06 | 2016-12-06 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2017040953A1 (en) * | 2015-09-02 | 2017-03-09 | Wayne State University | Compositions and methods relating to rad6 inhibition |
US9662327B2 (en) | 2011-06-17 | 2017-05-30 | Agios Pharmaceuticals, Inc | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer |
US9724350B2 (en) | 2013-07-11 | 2017-08-08 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US9856279B2 (en) | 2011-06-17 | 2018-01-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9968595B2 (en) | 2014-03-14 | 2018-05-15 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
US9980961B2 (en) | 2011-05-03 | 2018-05-29 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US10017495B2 (en) | 2013-07-11 | 2018-07-10 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10029987B2 (en) | 2009-06-29 | 2018-07-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US10202339B2 (en) | 2012-10-15 | 2019-02-12 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US10376510B2 (en) | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
US10584131B2 (en) | 2018-08-03 | 2020-03-10 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10610125B2 (en) | 2009-03-13 | 2020-04-07 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
US10626122B2 (en) | 2015-12-09 | 2020-04-21 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
US10689414B2 (en) | 2013-07-25 | 2020-06-23 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
US11419859B2 (en) | 2015-10-15 | 2022-08-23 | Servier Pharmaceuticals Llc | Combination therapy for treating malignancies |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2699585T3 (en) * | 2006-12-15 | 2019-02-11 | Nantbio Inc | Triazine derivatives and their therapeutic applications |
CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
JP2012529518A (en) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Pyridyl-triazine inhibitors of hedgehog signaling |
KR20130031296A (en) | 2010-05-21 | 2013-03-28 | 케밀리아 에이비 | Novel pyrimidine derivatives |
DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
MX2013012233A (en) * | 2011-04-19 | 2014-01-23 | Bayer Pharma AG | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines. |
CN102250065B (en) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | Substituted triazine phenyl urea derivatives and application thereof |
RU2509770C2 (en) * | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Novel chemical compounds - 2,4-diamino-1,3,5-triazine derivatives for preventing and treating human and animal diseases |
WO2015047124A1 (en) * | 2013-09-26 | 2015-04-02 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Novel chemical compounds derived from 2,4-diamino-1,3,5-triazine for the prophylaxis and treatment of human and animal diseases |
RU2650518C2 (en) * | 2016-04-01 | 2018-04-16 | Общество с ограниченной ответственностью Фирма "ОЛБО" | Colorless organic phosphors |
CN107304189A (en) * | 2016-04-18 | 2017-10-31 | 北京大学 | A kind of triaizine compounds and its preparation method and application |
RU2683327C1 (en) * | 2018-04-05 | 2019-03-28 | Общество с ограниченной ответственностью Фирма "ОЛБО" | Colorless luminophores of phenylbenzazole series |
CN114874107B (en) * | 2022-07-12 | 2022-11-29 | 中山大学附属第七医院(深圳) | Amino lipid and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
WO2002083653A1 (en) * | 2001-04-11 | 2002-10-24 | Amgen Inc. | Triazinyl acrylamide derivatives as kinase inhibitors |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3041330A (en) * | 1960-06-29 | 1962-06-26 | American Cyanamid Co | Cellulosic derivatives of triazinylbenzophenones |
BE619875A (en) * | 1961-07-07 | 1900-01-01 | ||
JP3170697B2 (en) * | 1992-08-27 | 2001-05-28 | 山陽色素株式会社 | Pigment dispersant |
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6150362A (en) * | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
CZ299156B6 (en) | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use |
PT1169038E (en) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
JP2003523942A (en) | 1999-06-30 | 2003-08-12 | メルク エンド カムパニー インコーポレーテッド | SRC kinase inhibitor compounds |
DE10021246A1 (en) | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
ES2346513T3 (en) | 2000-07-24 | 2010-10-18 | Krenitsky Pharmaceuticals, Inc. | 5-ALQUINIL PIRIMIDINAS REPLACED THAT HAVE NEUROTROPHIC ACTIVITY. |
SK2142003A3 (en) | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
AU2002327627B2 (en) | 2001-09-14 | 2006-09-14 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
CN102151273B (en) * | 2002-02-05 | 2015-11-25 | 安斯泰来制药有限公司 | 2,4,6-triamino-1,3,5-triazine derivative |
GB0230089D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
WO2005003103A2 (en) | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
JP2007534624A (en) | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | Biaryl piperazinyl-pyridine analogues |
WO2005011703A1 (en) | 2003-08-04 | 2005-02-10 | Akzo Nobel N.V. | 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
WO2005111017A1 (en) | 2004-05-07 | 2005-11-24 | Janssen Pharmaceutica, N.V. | Triazine compounds as inhibitors of bacterial type iii protein secretion systems |
ES2699585T3 (en) * | 2006-12-15 | 2019-02-11 | Nantbio Inc | Triazine derivatives and their therapeutic applications |
-
2007
- 2007-12-14 ES ES15162488T patent/ES2699585T3/en active Active
- 2007-12-14 EP EP15162488.9A patent/EP2923703B1/en active Active
- 2007-12-14 CN CN2007800498388A patent/CN101583365B/en active Active
- 2007-12-14 US US11/956,883 patent/US7858782B2/en active Active
- 2007-12-14 EP EP07865684A patent/EP2120964A2/en not_active Withdrawn
- 2007-12-14 AU AU2007333925A patent/AU2007333925B2/en active Active
- 2007-12-14 CA CA2672893A patent/CA2672893C/en active Active
- 2007-12-14 JP JP2009541616A patent/JP5622393B2/en active Active
- 2007-12-14 EP EP11007839.1A patent/EP2425840B1/en active Active
- 2007-12-14 WO PCT/US2007/087576 patent/WO2008076883A2/en active Application Filing
-
2010
- 2010-12-17 US US12/971,786 patent/US8580786B2/en active Active
-
2014
- 2014-06-12 JP JP2014121825A patent/JP2014221771A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
US20040116388A1 (en) * | 1999-10-07 | 2004-06-17 | Amgen Inc. | Kinase inhibitors |
WO2002083653A1 (en) * | 2001-04-11 | 2002-10-24 | Amgen Inc. | Triazinyl acrylamide derivatives as kinase inhibitors |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10610125B2 (en) | 2009-03-13 | 2020-04-07 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
CN102573486A (en) * | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | Triazine derivatives and their therapeutical applications |
AU2010259002B2 (en) * | 2009-06-08 | 2014-03-20 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
EP2440051A1 (en) * | 2009-06-08 | 2012-04-18 | Abraxis BioScience, LLC | Triazine derivatives and their therapeutical applications |
EP2440051A4 (en) * | 2009-06-08 | 2012-12-19 | California Capital Equity Llc | Triazine derivatives and their therapeutical applications |
JP2012529513A (en) * | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Triazine derivatives and their therapeutic applications |
JP2012529512A (en) * | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Triazine derivatives and their therapeutic applications |
CN102573481A (en) * | 2009-06-09 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
EP2440056A4 (en) * | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
JP2012529517A (en) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Benzyl-substituted triazine derivatives and their therapeutic applications |
JP2012529527A (en) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ureidophenyl substituted triazine derivatives and their therapeutic applications |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
JP2012529528A (en) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Triazine derivatives and their therapeutic applications |
EP2440057A4 (en) * | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | Triazine derivatives and their therapeutical applications |
CN102573480A (en) * | 2009-06-09 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | Triazine derivatives and their therapeutical applications |
EP2440057A1 (en) * | 2009-06-09 | 2012-04-18 | Abraxis BioScience, LLC | Triazine derivatives and their therapeutical applications |
WO2010144550A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2440056A1 (en) * | 2009-06-09 | 2012-04-18 | Abraxis BioScience, LLC | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
US9409903B2 (en) | 2009-06-09 | 2016-08-09 | Nantbioscience, Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
AU2010258825B2 (en) * | 2009-06-09 | 2014-08-21 | Nantbio, Inc. | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
WO2010144522A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
CN102573480B (en) * | 2009-06-09 | 2015-06-10 | 加利福尼亚资本权益有限责任公司 | Triazine derivatives and their therapeutical applications |
US10029987B2 (en) | 2009-06-29 | 2018-07-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US11866411B2 (en) | 2009-06-29 | 2024-01-09 | Agios Pharmaceutical, Inc. | Therapeutic compounds and compositions |
US10988448B2 (en) | 2009-06-29 | 2021-04-27 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
USRE49582E1 (en) | 2009-06-29 | 2023-07-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US10711314B2 (en) | 2009-10-21 | 2020-07-14 | Agios Pharmaceuticals, Inc. | Methods for diagnosing IDH-mutant cell proliferation disorders |
US9434979B2 (en) | 2009-10-21 | 2016-09-06 | Shin-San Michael Su | Methods and compositions for cell-proliferation-related disorders |
US9982309B2 (en) | 2009-10-21 | 2018-05-29 | Agios Pharmaceuticals, Inc. | Method for treating cell proliferation related disorders |
US10632114B2 (en) | 2011-05-03 | 2020-04-28 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US11793806B2 (en) | 2011-05-03 | 2023-10-24 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9980961B2 (en) | 2011-05-03 | 2018-05-29 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9856279B2 (en) | 2011-06-17 | 2018-01-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9662327B2 (en) | 2011-06-17 | 2017-05-30 | Agios Pharmaceuticals, Inc | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer |
US9512107B2 (en) | 2012-01-06 | 2016-12-06 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9732062B2 (en) | 2012-01-06 | 2017-08-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US11505538B1 (en) | 2012-01-06 | 2022-11-22 | Servier Pharmaceuticals Llc | Therapeutically active compounds and their methods of use |
US10294215B2 (en) | 2012-01-06 | 2019-05-21 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9656999B2 (en) | 2012-01-06 | 2017-05-23 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10640534B2 (en) | 2012-01-19 | 2020-05-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US10717764B2 (en) | 2012-01-19 | 2020-07-21 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US11667673B2 (en) | 2012-01-19 | 2023-06-06 | Servier Pharmaceuticals Llc | Therapeutically active compounds and their methods of use |
US9850277B2 (en) | 2012-01-19 | 2017-12-26 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
WO2013133367A1 (en) * | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | Novel triazine derivative |
US10202339B2 (en) | 2012-10-15 | 2019-02-12 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9365526B2 (en) | 2012-12-31 | 2016-06-14 | Sun Pharmaceutical Industries Limited | Process for the preparation of dasatinib and its intermediates |
WO2014102759A2 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Process for the preparation of dasatinib and its intermediates |
US10028961B2 (en) | 2013-07-11 | 2018-07-24 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10946023B2 (en) | 2013-07-11 | 2021-03-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003640A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US11844758B2 (en) | 2013-07-11 | 2023-12-19 | Servier Pharmaceuticals Llc | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US9724350B2 (en) | 2013-07-11 | 2017-08-08 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US10376510B2 (en) | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US10172864B2 (en) | 2013-07-11 | 2019-01-08 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EA030199B9 (en) * | 2013-07-11 | 2021-08-26 | Аджиос Фармасьютикалз, Инк. | Therapeutically active compounds and methods of use thereof |
US10017495B2 (en) | 2013-07-11 | 2018-07-10 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10111878B2 (en) | 2013-07-11 | 2018-10-30 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
EA030199B1 (en) * | 2013-07-11 | 2018-07-31 | Аджиос Фармасьютикалз, Инк. | Therapeutically active compounds and methods of use thereof |
US10689414B2 (en) | 2013-07-25 | 2020-06-23 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US11021515B2 (en) | 2013-07-25 | 2021-06-01 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10799490B2 (en) | 2014-03-14 | 2020-10-13 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
US10449184B2 (en) | 2014-03-14 | 2019-10-22 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
US9968595B2 (en) | 2014-03-14 | 2018-05-15 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
US11504361B2 (en) | 2014-03-14 | 2022-11-22 | Servier Pharmaceuticals Llc | Pharmaceutical compositions of therapeutically active compounds |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
US10588985B2 (en) | 2015-09-02 | 2020-03-17 | Wayne State University | Compositions and methods relating to RAD6 inhibition |
WO2017040953A1 (en) * | 2015-09-02 | 2017-03-09 | Wayne State University | Compositions and methods relating to rad6 inhibition |
US11419859B2 (en) | 2015-10-15 | 2022-08-23 | Servier Pharmaceuticals Llc | Combination therapy for treating malignancies |
US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
US11648253B2 (en) | 2015-12-09 | 2023-05-16 | Novartis Ag | Thienopyrimidinone NMDA receptor modulators and uses thereof |
US11236104B2 (en) | 2015-12-09 | 2022-02-01 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
US11541057B2 (en) | 2015-12-09 | 2023-01-03 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
US10626122B2 (en) | 2015-12-09 | 2020-04-21 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10973825B2 (en) | 2015-12-09 | 2021-04-13 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
US11807650B2 (en) | 2016-12-22 | 2023-11-07 | Novartis Ag | NMDA receptor modulators and uses thereof |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
US11542264B2 (en) | 2018-08-03 | 2023-01-03 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10752633B2 (en) | 2018-08-03 | 2020-08-25 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10584131B2 (en) | 2018-08-03 | 2020-03-10 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2014221771A (en) | 2014-11-27 |
EP2120964A2 (en) | 2009-11-25 |
CA2672893C (en) | 2016-02-23 |
JP5622393B2 (en) | 2014-11-12 |
WO2008076883A3 (en) | 2008-10-16 |
US20110150763A1 (en) | 2011-06-23 |
ES2699585T3 (en) | 2019-02-11 |
US8580786B2 (en) | 2013-11-12 |
CN101583365B (en) | 2012-09-26 |
CA2672893A1 (en) | 2008-06-26 |
US7858782B2 (en) | 2010-12-28 |
EP2425840A1 (en) | 2012-03-07 |
CN101583365A (en) | 2009-11-18 |
EP2923703A1 (en) | 2015-09-30 |
EP2425840B1 (en) | 2015-04-08 |
JP2010513313A (en) | 2010-04-30 |
AU2007333925A1 (en) | 2008-06-26 |
EP2923703B1 (en) | 2018-09-19 |
AU2007333925B2 (en) | 2013-10-31 |
US20080176853A1 (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2923703B1 (en) | Triazine derivatives and their therapeutical applications | |
US20130023497A1 (en) | Triazine Derivatives and their Therapeutical Applications | |
CA2764785C (en) | Triazine derivatives and their therapeutical applications | |
AU2010258825B2 (en) | Ureidophenyl substituted triazine derivatives and their therapeutical applications | |
US9409903B2 (en) | Benzyl substituted triazine derivatives and their therapeutical applications | |
US20120178758A1 (en) | Styryl-triazine derivatives and their therapeutical applications | |
EP3261637B1 (en) | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | |
AU2014200528B2 (en) | Triazine derivatives and their therapeutical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780049838.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07865684 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009541616 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007333925 Country of ref document: AU Ref document number: 2672893 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4027/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007865684 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007333925 Country of ref document: AU Date of ref document: 20071214 Kind code of ref document: A |